Abstract
BACKGROUND: A novel hyaluronic acid (HA) injectable (Restylane Shaype, HA(SHA)) with high strength/firmness and enhanced HA concentration, optimized for lower face shaping has been developed. AIMS: This prospective, 8-week, multicenter, post-market study evaluated three treatment algorithms, i.e., the Shayping Technique, for subjects with multiple aesthetic needs, including HA(SHA) for chin augmentation alone/in combination with treatments for the lower face and midface with HA(DEF) (Restylane Defyne) and HA(LYF) (Restylane Lyft Lidocaine). PATIENTS/METHODS: Subjects ≥ 18 years were assigned to one of the following treatments: Group 1: HA(SHA) (chin); Group 2: HA(SHA) (chin) and HA(DEF) (marionette line areas laterally to the chin); Group 3: HA(SHA) (chin), HA(DEF) (marionette line areas laterally to the chin), and HA(LYF) (midface and/or nasolabial fold [NLF, piriform fossa] and/or jawline). Assessments included Global Aesthetic Improvement Scale (GAIS), subject and investigator satisfaction, and collection of adverse events (AEs). RESULTS: The GAIS responder rate ("improved," "much improved," or "very much improved") was 100% in all groups at Week 8 (primary endpoint) and Week 4 as assessed by the investigator and by subject self-assessment at Weeks 4 and 8. Overall subject and investigator satisfaction with treatment was high, and the safety profile for all product combinations was favorable, with no unexpected AEs. CONCLUSIONS: Treatment with HA(SHA) for chin augmentation alone/in combination with HA(DEF) and HA(LYF) for comprehensive lower face and midface lift was safe and effective, with 100% aesthetic improvement at 8 weeks post-injection. The Shayping Technique provides standardized guidance for practitioners to perform safe injections and achieve optimal aesthetic outcomes.